MarketCap
Facebook
X
TelegramAnnual report 2023
added 03-06-2024
Endo International plc Cost of Revenue 2011-2026 | ENDP
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Endo International plc
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 946 M | 1.09 B | 1.22 B | 1.44 B | 1.57 B | 1.63 B | 2.23 B | 2.63 B | 2.08 B | 1.23 B | 887 M | 973 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.63 B | 887 M | 1.49 B |
Quarterly Cost of Revenue Endo International plc
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 230 M | 234 M | 233 M | - | 261 M | 264 M | 273 M | - | 286 M | 318 M | 305 M | - | 348 M | 336 M | 389 M | - | 389 M | 388 M | 392 M | - | 413 M | 382 M | 404 M | - | 515 M | 539 M | 669 M | - | 557 M | 632 M | 689 M | - | 442 M | 439 M | 384 M | - | 341 M | 303 M | 213 M | - | 258 M | 273 M | 254 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 689 M | 213 M | 374 M |
Cost of Revenue of other stocks in the Drug manufacturers industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
5.82 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Agile Therapeutics
AGRX
|
8.98 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
6.19 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
26.8 M | - | - | $ 754 M | USA |
 |
Catalent
CTLT
|
3.43 B | - | - | $ 11.5 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
85.5 M | - | -39.89 % | $ 27.7 M | USA |
 |
DURECT Corporation
DRRX
|
1.72 M | - | - | $ 50.1 M | USA |
 |
Alimera Sciences
ALIM
|
10.8 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
76.1 M | - | -23.39 % | $ 1.76 M | USA |
 |
OrganiGram Holdings
OGI
|
104 M | $ 1.42 | 1.43 % | $ 402 M |  Canada |
 |
Avadel Pharmaceuticals plc
AVDL
|
15.3 M | - | - | $ 2.06 B |  France |
 |
Cumberland Pharmaceuticals
CPIX
|
6.59 M | $ 3.12 | 0.97 % | $ 43.9 M | USA |
 |
Tilray
TLRY
|
480 M | $ 6.72 | - | $ 4.15 B | Canada |
 |
Harrow Health
HROW
|
67.9 M | $ 37.1 | - | $ 1.36 B | USA |
 |
Canopy Growth Corporation
CGC
|
189 M | $ 1.08 | - | $ 116 M | Canada |
 |
Veru
VERU
|
11 M | $ 2.38 | - | $ 321 M | USA |
 |
Viatris
VTRS
|
8.99 B | $ 13.83 | - | $ 16.6 B | USA |
 |
Jupiter Wellness
JUPW
|
2.69 M | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
294 M | - | 1.15 % | $ 7.11 M | USA |
 |
cbdMD
YCBD
|
7.49 M | $ 0.75 | - | $ 3.23 M | USA |
 |
Evolus
EOLS
|
100 M | $ 4.33 | 1.41 % | $ 279 M | USA |
 |
Emergent BioSolutions
EBS
|
705 M | $ 8.24 | - | $ 422 M | USA |
 |
Sundial Growers
SNDL
|
56.1 M | $ 1.37 | - | $ 3.37 M | Canada |
 |
Organogenesis Holdings
ORGO
|
116 M | $ 2.38 | - | $ 313 M | USA |
 |
Pacira BioSciences
PCRX
|
170 M | $ 24.06 | - | $ 1.11 B | USA |
 |
PetIQ
PETQ
|
849 M | - | 1.64 % | $ 400 M | USA |
 |
ProPhase Labs
PRPH
|
52 M | - | - | $ 5.07 M | USA |
 |
Relmada Therapeutics
RLMD
|
4.04 K | $ 7.38 | - | $ 291 M | USA |
 |
Assertio Holdings
ASRT
|
35.4 M | $ 18.02 | - | $ 115 M | USA |
 |
Radius Health
RDUS
|
18.4 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
76.5 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
8.63 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
15.4 M | $ 1.01 | - | $ 50.4 M | USA |
 |
PLx Pharma
PLXP
|
4.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
8.82 M | $ 2.35 | 3.07 % | $ 2.92 M | USA |
 |
Zomedica Corp.
ZOM
|
10.4 M | - | -0.21 % | $ 98 M | USA |
 |
Rockwell Medical
RMTI
|
57.6 M | $ 0.94 | - | $ 33.8 M | USA |
 |
China Pharma Holdings
CPHI
|
4.28 M | $ 0.65 | - | $ 2.79 M |  China |
 |
TherapeuticsMD
TXMD
|
1.4 M | $ 2.05 | - | $ 23.7 M | USA |